Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide + Pembrolizumab in Metastatic TNBC
NCT02768701Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2016
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Progression Free Survival up to 5 years and Quantification of the Change in Regulatory T Cells up to 2 years. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02768701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768701.